Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Fate Therapeutics, Inc.NASDAQ: FATE

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $21.79M fell 25.2% year over year, behind the -23.9% change in trailing-twelve-month research & development. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at -30.4% a year.

Context

  • Research & development amounted to 1622.5% of revenue in FY2025, up 632.1 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.2% toward the trailing-twelve-month pace of -23.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.79M-14.3% QoQ
Last fiscal yearDec 2025
$107.83M-20.1% YoY
LTMMar 2026
$100.48M-23.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.2%——
1 year-20.1%——
3-year CAGR-30.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
107.83M USD
Year-over-year change
-20.1%
4-year CAGR
-15.9%

Research & Development vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -23.9% is the 6th highest of 10, against a peer median of -9.9%.
  • Research & development amounts to 1590.8% of revenue for FATE, versus a peer median of 547.8%.
FATE Competitors
Research & Development for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$312.43M USD+226.5%+70.8%—
ALECAlector, Inc.LTM Mar 2026$114.68M USD-37.7%-16.4%622.7%
FATEFate Therapeutics, Inc.LTM Mar 2026$100.48M USD-23.9%-30.4%1590.8%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$96.1M USD-9.9%+48.0%—
NKTXNkarta, Inc.LTM Mar 2026$88.91M USD-7.1%-0.2%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M USD-33.8%+0.5%473.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
PEPGPepGen Inc.LTM Mar 2026$58.35M USD-32.7%+9.5%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$51.51M USD-27.2%-33.9%—
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
Peer median (excluding FATE) —-9.9%+0.5%547.8%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.